Isolation of antibodies specific to a single conformation-dependant antigenic determinant on the EG95 hydatid vaccine  by Read, A.J. et al.
I
d
A
a
b
c
a
A
R
R
2
A
A
K
E
H
R
C
1
g
o
w
t
o
h
h
h
t
m
H
i
i
r
M
f
0
dVaccine 27 (2009) 1024–1031
Contents lists available at ScienceDirect
Vaccine
journa l homepage: www.e lsev ier .com/ locate /vacc ine
solation of antibodies speciﬁc to a single conformation-dependant antigenic
eterminant on the EG95 hydatid vaccine
.J. Reada,∗, J.L. Caseyc, A.M. Coleyc, M. Foleyc, C.G. Gaucia, D.C. Jacksonb, M.W. Lightowlersa
The University of Melbourne, Veterinary Clinical Centre, 250 Princes Highway, Werribee, Victoria 3030, Australia
The University of Melbourne, Department of Microbiology and Immunology, Parkville, Victoria 3010, Australia
AdAlta Pty Ltd., Department of Biochemistry, La Trobe University, Victoria 3086, Australia
r t i c l e i n f o
rticle history:
eceived 25 September 2008
eceived in revised form
1 November 2008
ccepted 28 November 2008
vailable online 16 December 2008
a b s t r a c t
EG95 is a recombinant vaccine protein that elicits protection against hydatid disease in sheep. Previ-
ous studies have shown that the host-protective epitopes on EG95 depend on correct conformation and
cannot be represented by simple “linear” peptides. By screening random peptide phage display libraries
with polyclonal antibodies directed against conformation-dependant epitopes of EG95, we have selected
a number of peptides that mimic these epitopes. The selected peptides did not show sequence homol-
ogy to EG95. Antigen binding assays involving these peptides have provided evidence of at least four
conformationally-dependant epitope regions on EG95. One of the selected peptides, E100, has been usedeywords:
chinococcus granulosus
ydatid
andom peptide phage display
onformation-dependant epitope
to purify antibodies from anti-sera raised in sheep vaccinated with EG95. This yielded monospeciﬁc anti-
bodies capable of recognizing recombinant EG95 in ELISA and native EG95 in Western blot assays. This
antibody was demonstrated to be effective in antibody-dependant complement-mediated in vitro killing
of Echinococcus granulosus oncospheres. Peptide E100 may represent the basis for a quality control assay
for EG95 production, and has the potential to become a component of a synthetic peptide-based vaccine
against E. granulosus.
Crow. Introduction
The metacestode life stage of the taeniid cestode Echinococcus
ranulosus is the aetiological agent of cystic hydatid disease (CHD)
f humans. CHD is a disease which often affects rural communities,
ith a global distribution [1]. Surveys involving populations where
he disease is highly endemic have shown prevalence in the order
f 2% to 6%. Although mortality directly associated with CHD is not
igh, there is often signiﬁcant morbidity. A number of researchers
ave documented the impact of the disease in terms of human
ealth andﬁnancial losses to communities [2]. Thedog is thedeﬁni-
ive host in the life cycle of the parasite, while various herbivorous
ammals, especially sheep, become infected as intermediate hosts.
umans are infected by fortuitously ingesting parasite eggs presentn the faeces of the deﬁnitive host.
A recombinant vaccine has been developed for prevention of
nfection in the intermediate host [3] and the bacterially expressed
ecombinant antigen is designated EG95. EG95 has been shown to
∗ Corresponding author at: Elizabeth Macarthur Agricultural Institute, Private
ail Bag 8 Camden, NSW 2570, Australia. Tel.: +61 2 4640 6332;
ax: +61 2 4640 6429.
E-mail address: andrew.j.read@dpi.nsw.gov.au (A.J. Read).
264-410X Crown Copyright © 2008 Published by Elsevier Ltd.
oi:10.1016/j.vaccine.2008.11.096
Open access under CC BY licen Copyright © 2008 Published by Elsevier Ltd.
induce between 95% and 100% protection in sheep against a chal-
lenge infection with E. granulosus eggs [3], and has proved to be
highly effective in preventing infection in New Zealand, Australia
and Argentina [4]. The EG95 vaccine developed for sheep may be
a useful tool to reduce the incidence of transmission of hydatid
disease to humans in endemic areas [5].
There is signiﬁcant evidence that antibody-mediated
complement-dependant lysis of oncospheres is the major mode
of protection against infection amongst the taeniid cestodes [6].
Immunity can be passively transferred from a previously infected
animal or animal vaccinated with early larval (oncosphere) anti-
gens via colostrum or whole serum [5]. Sheep immunised with
either E. granulosus oncospheres [7] or the EG95 antigen [3,8]
produce antibodies which are capable of killing E. granulosus onco-
spheres in vitro. Taken together these pieces of evidence suggest
that anti-EG95 antibodies play a crucial role in vaccine-induced
protection.
It has been predicted from the amino acid sequence of EG95 that
the protein is dominated by a ﬁbronectin type III (FnIII) domain [9].
Open access under CC BY license.Although linear epitopes on the protein have been identiﬁed [10]
immunisationwithpeptides representing these linear epitopes [11]
or larger polypeptides lacking the complete FnIII domain [8] failed
to induce protection against infection. It has been postulated that
the protective epitope(s) of EG95 are dependant on the correct con-
nse.
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ormation of EG95 and cannot therefore be properly represented
y simple peptide sequences, furthermore the important epitopes
ost likely involve the FnIII domain [8].
By inserting a randomised nucleotide sequence of a given length
nto M13 ﬁlamentous bacteriophage (phage) DNA it is possible to
roduce random peptide phage display (RPPD) libraries which can
isplay many millions of different peptides. Such RPPD libraries
ave been used to select peptides that bind speciﬁcally to a given
arget [12] enabling the identiﬁcation of “mimotopes” that mimic
conformation-dependant epitope [13]. Mimotopes often lack any
equence homology to the original antigen, but neverthelessmimic
he three dimensional structure of the epitope thereby allowing
ecognition and binding of antibody elicited by the original protein
ntigen. Phage displayed peptides have been usefully applied in a
umber of vaccine-related studies [14] including studies involving
cestode parasite [15].
The identiﬁcation of ligands that are capable of mimicking the
rotective epitope(s) of EG95mayassist in quality controlmeasures
or the production of the recombinant vaccine and could even lead
o the development of a totally synthetic vaccine against CHD. Pre-
ious attempts to identify mimotopes of conformation-dependant
pitopes of EG95 (11) have been unsuccessful resulting in the selec-
ion of peptides that correspond to linear sequences of amino acids
ithin EG95 and which represent non-protective epitopes. In this
tudy we have applied the strategy of screening two RPPD libraries
ith polyclonal antibodies that are speciﬁcally directed against the
onformation-dependant epitope(s) of the protein. We show that
ntibodies directed against conformational-dependant epitope(s)
ay bepuriﬁed from the serumof sheep immunisedwith EG95 and
hat by screening these antibodies against RPPD libraries, peptides
ay be selected that allow the puriﬁcation of antibodies against a
ingle conformation-dependant epitope.
. Materials and methods
.1. Source of antibodies
The isolation and characterisation of polyclonal antibodies
gainst conformational epitopes of EG95 have been described else-
here (A.J. Read, C.G. Gauci and M.W. Lightowlers, under review).
rieﬂy, pooled anti-sera were derived from sheep immunised with
G95-GST. Afﬁnity chromatography was used to deplete the sera
f antibody speciﬁcities to GST and linear epitopes of EG95. The
era depleted of these speciﬁcities were then afﬁnity puriﬁed on
n EG95-GST chromatography column. Antibodies eluted from this
olumn were used in afﬁnity selection experiments using RPPD
ibraries and referred to as anti-cEG95 antibodies. The GST afﬁnity
uriﬁcation columnused in the depletion stepwas used to generate
olyclonal anti-GST antibodies (anti-GST).
.2. Source of random peptide phage display libraries
Two non-constrained random peptide phage display libraries
ere used to select peptides bound by anti-cEG95. These are the
h.D-12 Phage Display Kit (New England Biolabs, USA) [16] (Library
) and a 20-mer library (Library 2, provided by AdAlta Pty Ltd) [17].
ach library carried a random DNA insert encoding a peptide near
he N terminus of the pIII minor coat protein at one end of the ﬁla-
entous phage. The Ph.D-12 library is based on the M13KE phage
ector and expresses a 12-mer peptide while the 20-mer library is
ased on the fUSE5 vector [12] and expresses a 20-mer peptide..3. Afﬁnity selection
The afﬁnity selection of phage that is speciﬁcally bound by
nti-cEG95 was conducted in a manner similar to that described(2009) 1024–1031 1025
elsewhere [17]. Anti-cEG95 antibodies or anti-GST antibodies in
100lwere adsorbedovernight at 4 ◦Conto tenwells in amicrotitre
plate (Maxisorp, NUNC, Denmark). The wells were then emp-
tied and blocked for 2h with 5% skim milk powder in phosphate
buffered saline (145mMNaCl, 2.7mMKCl, 12mMNa2HPO4, 1.2mM
KH2PO4, pH 7.4) (SMPBS). Approximately 11×1010 transforming
units (TU) of phage per ml was pre-incubated for 1h in SMPBS
and following removal of the blocking agent, 100l of the phage
solution was added to each well for a period of 2h. The solution
containing phage was then removed and the wells were washed.
The stringency of selection was increased with each round of afﬁn-
ity selection by increasing the number ofwashes performed. Bound
phages were eluted from the wells by the addition of 100l 0.1M
Glycine/HCl, pH 2.2 for 10min. The eluate was pooled and neu-
tralised with 1M Tris. Eluted phages were ampliﬁed using E. coli
(ER2537) for Library 1 and E. coli (K91) for Library 2. A total of
four rounds of afﬁnity selection were undertaken for each library.
The DNA sequence of isolated phage clones was determined using
an Applied Biosystems PRISMTM automated sequencing system
with the ABI BigDyeTM Terminator sequencing kit. The amino acid
sequence of each clone was deduced from the DNA sequence.
2.4. Phage indirect ELISA
Afﬁnity puriﬁed antibodies (anti-cEG95 and anti-GST) were
adsorbed onto microtitre plates overnight at 4 ◦C. Non-speciﬁc
binding was blocked by adding SMPBS for 1h at room temperature.
Phages were added to the washed plates either at a set concentra-
tion or following serial dilution in SMPBS. Phageswere left for 1h at
room temperature. Levels of phage binding were assessed through
the addition of a mouse monoclonal anti-M13 HRP (Pharmacia,
Sweden). Peroxidase activity was detected by adding a tetramethyl
benzidine (TMB) substrate (Sigma, USA) to the test wells for 30min
before stopping the reaction with 0.5M H2SO4. Absorbance was
measured at 450nm.
2.5. Antibody indirect ELISA
Recombinant proteins EG95-MBP (EG95 bound toMaltose Bind-
ing Protein afﬁnity tag) or GST were adsorbed onto microtitre
platesovernight at4 ◦C.Non-speciﬁcbindingwasblockedbyadding
SMPBS for 1h at room temperature. Serially diluted serum or afﬁn-
ity puriﬁed antibody samples were added to the wells for 1h at
room temperature and levels of IgG were assessed by the addition
of a polyclonal donkey anti-sheep IgG-HRP (Sigma, USA) to each
well for 1h at room temperature. Peroxidase activity was detected
by adding a TMB substrate to the test wells for 30min before stop-
ping the reaction with 0.5M H2SO4. Absorbance was measured at
450nm.
2.6. Synthesis of peptides
Solid-phase peptide syntheses were performed using 9-
ﬂuorenylmethoxycarbonyl (Fmoc) chemistry either manually or in
an automated solid-phase synthesizer (SymphonyTM automated
peptide synthesizer, Rainin-PTI Woburn, USA) on a cleavable resin
(TentaGel S-RAM, Rapp Polymere GmbH, Germany). Peptides were
analysedbyreversephasechromatographyusingVydacC8columns
(4.6mm×250mm) installed in a Waters HPLC system and subse-column (10mm×300mm).
The peptide E3, yvalqgsmfdrvrvfwmarg, was found to be insol-
uble in aqueous solution. Solubility was improved by adding ﬁve
lysine residues to the amino terminus. This peptide is referred to as
K5-E3.
1 ine 27
2
u
w
i
a
(
d
0
a
w
b
(
c
b
2
w
g
d
m
E
a
n
c
f
d
t
f
d
b
C
2
v
S
B
t
b
(
s
T
i
a
t
U
a
C
2
L
t
a
U
w
t
o
s026 A.J. Read et al. / Vacc
.7. Afﬁnity puriﬁcation using E100/G1
Activated NHS-Sepharose® was prepared according to the man-
facturer’s instructions. Brieﬂy, pre-swollen NHS-Sepharose beads
ere mixed with free synthetic peptides E100 and G1 dissolved
n coupling buffer (0.2M NaHCO3, 0.5M NaCl, pH 8.3). Remaining
ctivated sites on the beads were blocked with Tris buffered saline
145mM NaCl, 20mM Tris, pH 7.4).
Pooled serum from sheep immunised with EG95-GST was
iluted in an equal volume of binding buffer (0.01M Na2HPO4,
.15M NaCl, 0.01M EDTA, pH 7.0). The anti-serum solution was
pplied to the afﬁnity columns under gravity. Unbound material
as removed by washing columns with up to 50ml of binding
uffer. Bound antibodies were eluted under low pH conditions
0.1M Glycine/HCl, 0.15M NaCl, pH 2.6). The eluted fractions were
ollected and adjusted to pH 7.5. The fractions with indirect anti-
ody ELISA absorption values >0.75 were pooled.
.8. Immuno-blots of recombinant proteins
Nitrocellulose 0.2m (HybondTM ECLTM, GE Healthcare, USA)
as pre-wetted in Towbin Transfer Buffer (25mM Tris, 193mM
lycine, 20% methanol, pH 8.4). Protein concentrations were
etermined using the Biorad Protein Assay (Bio-Rad, USA). One
icrogram of each of the recombinant proteins EG95-GST, GST and
G95-MBPwas pipetted on to the nitrocellulose. The blotwas dried
nd incubated for 1h in SMPBS-0.05% Tween (SMPBST) to block
on-speciﬁc binding sites. Incubation with primary antibodies was
arried out for 1h at room temperature. Whole serum pools taken
rom sheep prior to and after immunisation with EG95-GST were
iluted 1:2000 in SMPBST. Afﬁnity puriﬁed antibodieswere diluted
o 1g/ml in SMPBS. Themembraneswere subsequently incubated
or 1h at room temperature with a 1:2000 dilution of a polyclonal
onkey anti-sheep IgG-HRP conjugate diluted in SMPBST. The anti-
odies on the paper were detected and visualised by Enhanced
hemiluminescence (ECL; Boehringer Mannheim, Germany).
.9. Western blots of native antigens
E. granulosus oncospheres were harvested, hatched and acti-
ated [7]. The oncosphereswere solubilised in SDS, separated using
DS-PAGE (10%) and transferred to a nitrocellulose ﬁlter (0.2m,
io-Rad, USA) by electrophoresis (Trans-Blot, Bio-Rad, USA) using
he manufacturer’s instruction. Non-speciﬁc binding sites were
locked with 5% (w/v) skim milk powder in Tris buffered saline
145mM NaCl, 20mM Tris, pH 7.4) (SMTBS) overnight at 4 ◦C. All
erum was used at a 1:5000 dilution in TBS containing 0.1% (v/v)
ween and 5% (w/v) skim milk powder. Afﬁnity puriﬁed antibod-
es were used at a concentration of 1g/ml. Detection of bound
ntibody was achieved through the application of a 1:2000 dilu-
ion of polyclonal donkey anti-sheep IgG-HRP conjugate (Sigma,
SA) diluted in PBST containing 5% (w/v) skim milk powder. The
ntibodies on the paper were detected and visualised by Enhanced
hemiluminescence (ECL; Amersham Biosciences).
.10. Oncosphere killing
Adult E. granulosus were harvested as described by Heath and
awrence [18].Wholewormswere brieﬂyhomogenised andpassed
hrough an 80m sieve to remove debris. Eggs were suspended
nd washed in PBS. Eggs were resuspended in 1% pepsin (Sigma,
SA) and 1% (v/v) concentrated HCl in 0.85% saline. The suspension
as gently mixed at 37 ◦C for 1h. Following centrifugation at 500g,
he supernatant was discarded and the tube ﬁlled with a solution
f 1% pancreatin (Sigma, USA), 1% NaHCO3 and 5% sheep bile. The
uspension was gently mixed at 37 ◦C for 30min.(2009) 1024–1031
The oncospheres were centrifuged (1000× g×2min) and the
supernatant discarded. Oncospheres were separated from the
embryophoric blocks by thorough mixing in Percoll Cultivation
Medium (100ml 10× NCTC 135 (Sigma, USA), 10ml 200mM Glu-
tamine, 100mg gentamicin, 900ml Percoll (Sigma, USA)) and
centrifuging themixture at 1000× g for 10min. The activated onco-
spheres were removed from the top of the solution and added to
RPMI 1640 (Gibco, Invitrogen, USA), centrifuged and washed twice
in RPMI culturemedium. The number of activated oncosphereswas
estimated using an improved Neubauer haematocytometer count-
ing chamber at 200 fold magniﬁcation.
Oncosphere cultures were propagated in 96-well ﬂat bottomed
Nunc Culture plates. Afﬁnity puriﬁed antibodies were serially
diluted from 68g/ml to 0.85g/ml. Each well contained 100l
of afﬁnity puriﬁed antibodies, 100l of RPMI culture medium,
approximately 20 activated oncospheres and 50l of serum from
a 6 month old naïve Merino wether. Penicillin, gentamicin and
amphotericin were added to the cultures to give a ﬁnal concentra-
tion of 50U/ml, 50g/ml and 125ng/ml respectively. All cultures
were performed in duplicate and plates were cultured in a 5% CO2
atmosphere at 37 ◦C in a humidiﬁed incubator. Serially diluted sera
from sheep immunised with EG95-GST and from naïve sheep were
usedas controlswithineachcultureplate.After10days, thenumber
of living oncospheres was counted and compared with the num-
ber surviving in the naïve serum samples. Results were expressed
as the total number of oncospheres surviving within a culture
well.
3. Results
Afﬁnity puriﬁed polyclonal anti-cEG95 and anti-GST antibody
were used to afﬁnity select peptides from the 20-mer and 12-mer
random peptide libraries. The progress of the afﬁnity selection pro-
cedure was monitored by performing a phage indirect ELISA on an
aliquot from each round of panning. The phage pools were exam-
ined for binding to anti-cEG95 antibody, anti-GST antibody and a
zero antibody “mock” ELISA to observe evidence that phage were
being selected for binding to the target antibody (Fig. 1).
Bothexperiments resulted in an increase in reactivity toward the
target antibodyover theﬁrst three roundsof panning. The reactivity
toward the non-target antibody showed a slight increase during
these panning rounds.Where no antibodywas present in the ELISA,
there was no increase. The fourth round of panning against anti-
cEG95 resulted in a slight decrease in reactivity whereas the fourth
round of panning against anti-GST resulted in a slight increase in
reactivity (data not shown). The unselected library (Round 0) and
R1 phage displayed similar levels of reactivity to the background
(no phage) reactivity.
Twelve phage clones from the 20-mer library—E1, E2, E3, E6,
E14, E20, E30, E33, E45, E55, E68 and E114, and eight from the
12-mer library—E91, E99, E100, E104, E105, E106, E108 and E110
were selected against anti-cEG95 and shown by DNA sequencing to
contain different peptides (Table 1).
The amino acid sequences of the selected peptides were exam-
ined for homology to EG95. Phage clone E14 was found to display
ﬁve residues that aligned with the EG95 sequence (Table 1). None
of the other peptides could be aligned to the sequence of EG95.
The phage clone G1, which was selected with afﬁnity puri-
ﬁed anti-GST antibodies, demonstrated signiﬁcant homology to the
sequence of GST. Four residues over a seven residue sequence were
the same in both G1 and GST.
One phage clone, R1, was chosen at random from the library
without any afﬁnity selection. There was no apparent sequence
homology between this peptide and either EG95 or GST and this
peptide was used as a negative control in subsequent experiments.
A.J. Read et al. / Vaccine 27 (2009) 1024–1031 1027
Fig. 1. Indirect ELISA showing the enrichment of speciﬁc phage during the afﬁn-
ity selection process. Phages were afﬁnity selected on anti-cEG95 using Library 1
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Table 2
Alignment of amino acid sequences within each group determined in the peptide
competition ELISA. Consensus sequences were determined to be present when two
or more amino acid residues aligned. Epitope labels correspond to groupings found
in Fig. 4. Underlined residues derived from phage pIII protein.
Epitope group Phage Amino acid sequence
Epitope
A
E3 YVALQGSMFDRVRVFWMARG
E91 NRLFDRVDRFYA
E104 TLFGRMEHYFN
Consensus A LFDRVXXF
Epitope
B
E14 GFGKDITTGHSFTHKSNNDPGAAG
E100 HYKWLNDPLAAW
E108 LDKRNNDPFHLP
Consensus B KXNNDPXAA
Epitope
C
E99 GKPGWLLDNVAL
E105 ISTSKPAWKLAN
Consensus C KPXWXLXNA) and Library 2 (B). Pooled phages were ampliﬁed and 1010 TU/ml were added
o microtitre wells preadsorbed with anti-cEG95, anti-GST or skim milk powder.
hages were detected with anti-M13 HRP monoclonal antibody. R1 phage is a clone
elected randomly from the library without any selection pressure.
The relative avidities of phage toward anti-cEG95 and anti-GST
ntibodies were measured using phage indirect ELISA. The indi-
idual phage clones were titrated against anti-cEG95, anti-GST or
ith no antibody present (Fig. 2) enabling a determination as to
hich of the phage clones selected by panning against anti-cEG95
referentially bound to anti-cEG95 antibody.
able 1
educed amino acid sequence of the displayed peptides of phage clones selected
fter four rounds of biopanning with anti-cEG95 antibody as a target. Alignment of
eptide E14 to EG95. Aligned residues indicated in bold.
1 CIFPLCLGRPIAASYPPKTR
2 LNSRHTDKGTVQFALIAVRG
3 YVALQGSMFDRVRVFWMARG
6 ACSDRFLRRPMCLPPHVVFL
14 GFGKDITTGHSFTHKSNNDP
20 TTGNLSLDLLIATRFSSHGK
30 IHTDRPAWKYVGALPVIHVR
33 NSNFTVHSNYWYWNRYIPPV
45 TNLLYMLNTEAQYKALFMRK
55 ILPNPIHHTWLPFKLSHNLP
68 GCSYPMCRFNVVRFTGLSLL
114 GLFDLTNYYYLSRGTQIKGT
91 NRLFDRVDRFYA
99 GKPGWLLDNVAL
100 HYKWLNDPLAAW
104 TLFGRMEHYFN
105 ISTSKPAWKLAN
106 CIPPLCKLRLHE
108 LDKRNNDPFHLP
110 SVSVGMKPSPRP
14 GFGKDITTGHSFTHKSNNDP
G95 110KKTILGFTVDIETPRAGKKESTVMTSGSAL139Epitope
D
E1 CIFPLCLGRPIAASYPPKTR
E106 CIPPLCKLRLHE
Consensus D CIXPLCXXR
Selected phage clones were then subjected to a competitive
phage indirect ELISA to determine if the binding to anti-cEG95 anti-
body could be inhibited by EG95-MBP. EG95-MBP was used as the
inhibitor in these assays rather than the protein that the anti-sera
was raised against (EG95-GST). This was to assess the EG95 compo-
nent without having the results confounded by the possibility that
the phage were binding to anti-GST antibodies.
The results indicate that phage clones E2, E20, E30, E33, E55,
E110 and E114 were not inhibited from binding to anti-cEG95 anti-
bodies by either EG95-MBP or GST (Fig. 3). The remaining phage
clones were inhibited from binding to anti-cEG95 by EG95-MBP
and could be divided into two groups (i) those that are inhibited
from binding to a level that approached complete inhibition—E99,
E105 and E108, and (ii) those that were partially inhibited—E1, E3,
E6, E14, E45, E68, E91, E100, E104 and E106.
Thirteen synthetic peptides were examined for their ability to
compete with twelve phage clones for binding to anti-cEG95 anti-
bodies. This experiment was to determine whether there were
groups of peptides that mimicked the same epitope(s) on EG95.
The results (Fig. 4) of these competitive phage indirect ELISAs indi-
cate that with the exception of E105, each peptide competed with
its corresponding phage clone for binding to the anti-cEG95 anti-
bodies. Peptide E106 was not synthesised. Based on the pattern of
peptide competition we placed the phage clones we examined into
groups of putative epitopes:
- EpitopeA, clones E3, E91 andE104were each inhibited frombind-
ing to anti-cEG95 antibodies by peptides K5-E3, E91 and E104.
- Epitope B, clones E14, E100 and E108 were each inhibited from
binding to anti-cEG95 antibodies by peptides E100 and E108. Pep-
tide E14 showed a diminished degree of inhibition to these phage
clones.
- Epitope C, clones E99 and E105 were each inhibited from bind-
ing to anti-cEG95 antibodies by peptide E99. Peptide E105 did
not inhibit its corresponding phage clone, nor did it inhibit phage
clone E99.
- Epitope D, clones E1 and E106 were each inhibited from binding
to anti-cEG95 antibodies by peptide E1.
Phage E45 was inhibited from binding to anti-cEG95 antibodies
by peptide E45, and to a diminished extent by peptides E104 and
K5-E3. Phage E6 was inhibited from binding to anti-cEG95 antibod-
ies by peptide E6. Consensus motifs were found in the amino acid
sequences present in epitopes A, B, C and D (Table 2).
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og of the phage concentration.
Peptide E100 was the most effective of the selected peptides for
se as an afﬁnity puriﬁcation ligand (data not shown) and together
ith peptide G1 was chosen as an afﬁnity puriﬁcation ligand. NHS-
epharose beads were linked to peptide E100 and peptide G1 to
roduce two afﬁnity puriﬁcation columns. Afﬁnity puriﬁcation of
ntibodies from sheep immunised with EG95-GST was carried out
sing these two columns as targets. Eluted antibodies were neu-
ralised and collected as 500l fractions. The reactivity of each
luted fraction toEG95-MBPandGST inantibody indirect ELISAsare
hown in Fig. 5. The fractions that were eluted from the E100 pep-
ig. 3. Competitive phage indirect ELISA. Anti-cEG95 antibodies were adsorbed onto mic
ﬁnal concentration of 250g/ml in PBS with 5% skim milk powder. Phage binding was minding was quantiﬁed by the Phage Capture ELISA. Abscissa values are the common
tide column showed speciﬁc reactivity to EG95-MBP with a peak
in fractions 3 and 4; there was low reactivity to GST. The fractions
eluted from the G1 peptide column showed speciﬁc reactivity to
GST, with a peak of reactivity in fraction 4, and low reactivity to
EG95-MBP.Dot blot assays were used to further assess the speciﬁcity of the
antibodies afﬁnity puriﬁed by each of the two peptides, E100 and
G1, and also anti-EG95-GST anti-sera from which the antibodies
were originally puriﬁed by afﬁnity chromatography. Pooled sera
obtained from sheep prior to immunisation were also examined
rotitre plates and a mixture of phage and protein competitor (EG95-MBP or GST) at
easured. Displayed values are the mean± SEM of duplicate wells.
A.J. Read et al. / Vaccine 27 (2009) 1024–1031 1029
F tibod
t indivi
r s.
b
s
E
o
E
p
i
i
S
r
a
a
i
E
i
w
r
o
w
a
a
o
t
wig. 4. Effect of synthetic peptides on the binding of phage clones to anti-cEG95 an
o thirteen synthetic peptides. The ordinates are the percentage of inhibition that
epresent phages displaying similar patterns of inhibition by synthetic free peptide
y dot blot assays. The results (Fig. 6) show that pooled anti-
era obtained from sheep immunised with EG95-GST reacted with
G95-GST, GST and with EG95-MBP. Antibodies afﬁnity puriﬁed
n peptide E100 reacted exclusively with proteins that contained
G95, that is, EG95-GST and EG95-MBP, and antibodies afﬁnity
uriﬁed on peptide G1 reacted with EG95-GST and GST. Pre-
mmune pooled sera showed only background levels of reactivity
n this assay.
The antibodies that were afﬁnity puriﬁed on peptide E100-
epharose or G1-Sepharose were then assessed for the ability to
eact with native antigens in E. granulosus using a Western blot
ssay. The pooled anti-EG95-GST anti-sera reacted strongly with
n oncosphere antigen with a relative molecular weight of approx-
mately 23kDa (Fig. 7). The antibodies afﬁnity puriﬁed on peptide
100 also reacted with this same antigen whereas antibodies afﬁn-
ty puriﬁed on peptide G1 or pre-immune anti-sera did not react
ith any oncosphere antigens.
Anti-EG95-GST, anti-E100antibodyandanti-G1antibodyprepa-
ations were assessed for their ability to kill E. granulosus
ncospheres in vitro. Pooled sera obtained from sheep immunised
ith EG95-GST and corresponding pre-immune sera were used
s controls. The results are shown in Fig. 8. The anti-EG95-GST
nti-sera were observed to kill oncospheres, with only a single
ncosphere surviving. Oncosphere killing was observed in all cul-
ures containing antibodies puriﬁed on E100 peptide. The killing
as complete for antibody concentrations greater than or equal toy. Individual panels each represent a single phage clone. The abscissas correspond
dual peptides cause relative to the addition of no inhibitor. Putative Epitopes A–F
3.4g/ml. Antibodies afﬁnity puriﬁed on G1 peptide were unable
to kill oncospheres as was pre-immune sera.
4. Discussion
The data presented here indicates that peptide E100 mimics
of a conformation-dependant and protective epitope of EG95. The
peptide could be used to purify a sub-population of antibodies pro-
duced following immunisation with EG95-GST and these afﬁnity
puriﬁed antibodies could bind to native EG95 and kill E. granulosus
oncospheres. The results demonstrate that random peptide phage
display libraries can be used to identify molecular mimics of EG95
and, in this case, putatatively protective epitopes.
The random peptide phage display libraries that we used con-
tained between 108 and 1010 unique peptides and were used to
select peptides that bound anti-cEG95 antibodies. The selection
process does not distinguish between those peptides that bind to
the complementarity-determining regions and those that bind to
other parts of the antibody. The method of biopanning that we
used was able to select peptides from both phage display libraries
and enrich the speciﬁc binding phage during each of the ﬁrst three
rounds of panning.
Theslightdecrease in theELISAsignal following the fourth round
of biopanning may have been due to the presence of a greater
abundance of phages with higher avidity for the target in the third
round pool when compared to the fourth round pool. Some phage
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Fig. 7. Western blots of E. granulosus oncosphere antigens reacted with sheep anti-
anti-GST antibodies), but did not have absorbances as high as oth-
ers in the ELISA. Presumably these phage displayed peptides were
reactingwith a sub-population of antibody thatwas ofminor speci-ig. 5. Antibody capture ELISA results of afﬁnity puriﬁcation fractions. Afﬁnity puri-
ed antibody fractions were examined for ability to bind EG95-MBP () or GST (©).
he antibodies afﬁnity puriﬁed to E100 peptide are represented in panel A. The
ntibodies afﬁnity puriﬁed to G1 peptide are represented in panel B.
isplayed peptides can confer a selective growth advantage (or dis-
dvantage) for the bacterial host [19]; possibly therefore phage
btained from the fourth round of biopanning may have had such a
rowth advantage but lower avidity toward the selecting antibody.
he relatively small decrease in ELISA signalwould suggest that this
hange in the ratio of selected phages in the pool was not signiﬁ-
ant, and would be unlikely to have eliminated any phage clones
hat were important in providing the ELISA signal. Other possible
ig. 6. Dot blot assay. Recombinant proteins EG95-GST, GST and EG95-MBP were
lotted on to nitrocellulose membrane. The proteins were probed with pooled anti-
era from sheep immunised with EG95-GST (column A), naïve pooled sera (column
), antibodies afﬁnity puriﬁed on E100-NHS-Sepharose (columnC) and antibodies
fﬁnity puriﬁed on G1-NHS-Sepharose (column D).sera to EG95-GST (lane A), naïve sera (lane B), antibodies afﬁnity puriﬁed on E100-
NHS-Sepharose (lane C) and antibodies afﬁnity puriﬁed onG1-NHS-Sepharose (lane
D). Lane E is a Coomassie stained SDS-PAGE of the oncosphere antigens.
explanations for the decrease in ELISA signal in the ﬁnal round of
panning include the possibility of inaccuracies in the phage titre or
increased protease activity in this sample. These possibilities again
do not diminish the fact that speciﬁc afﬁnity puriﬁcation occurred
in this ﬁnal round of biopanning.
Only one of the selected displayed peptides showed sequence
homology to EG95. This area of EG95 was not one of the areas
thought to contain linear epitopes [10].Noneof the sequencesof the
remaining selected peptides aligned with the amino acid sequence
of EG95. Prima facie this may appear to indicate that the use of
polyclonal antibodieswith linear epitope speciﬁcities removedwas
successful at overcoming the bias toward selecting peptides that
bind to linear epitopes.
The indirect ELISA used here allowed phage to be differenti-
ated into those that bound speciﬁcally to anti-EG95 antibodies
and those that did not. A number of the phage clones appeared
to bind speciﬁcally to anti-EG95 antibodies (when compared toﬁcitywithin the anti-EG95antibodypopulation. Competitivephage
Fig. 8. Survival of E. granulosus oncospheres in vitro in the presence of pooled
anti-EG95-GST anti-sera (hatched bars), pre-immune sera (white bars), antibodies
afﬁnity puriﬁed on peptide E100 (black bars) and peptide G1 (grey bars). Sera in the
test wells were diluted from 1:2.5 through to 1:20. Afﬁnity puriﬁed antibodies were
diluted from 6.8g/ml to 0.85g/ml. Assays for each dilution were performed in
duplicate. Each individual bar represents the number of oncospheres (mean± SEM)
surviving after 10 days of culture.
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sity by fusion to the major coat protein of ﬁlamentous phage. Biol Chem
1997;378(6):517–21.A.J. Read et al. / Vacc
ndirect ELISA using EG95-MBP allowed some phage clones to be
liminated as potential mimetics (Fig. 3). These phage clones could
ot be inhibited from binding to anti-cEG95 by the addition of
G95-MBP. There are two possible causes for these peptides to be
nable to be competitively inhibited by EG95. The ﬁrst possibil-
ty is that the phage displayed peptide does not bind to the same
aratope as EG95, such peptides are not (by deﬁnition) mimotopes
f EG95. A second possibility is that these peptides have a signiﬁ-
antly higher avidity for the antibody than does EG95. When these
hage clones were titrated in the phage indirect ELISA, however,
hey had some of the lowest reactivities of the selected phages. In
rder for these phage clones to have a high afﬁnity for anti-cEG95
he peptides are likely to be binding to an antibody sub-population
f very minor speciﬁcity. By eliminating those peptides that were
ot speciﬁc for anti-cEG95 and those that could not be inhibited
rombinding to anti-cEG95 by EG95-MBP there are twelve peptides
hat act as conformation-dependant epitope mimics.
A portion of the anti-EG95 antibodies raised by immunising
heep with EG95-GST was able to be puriﬁed using peptide E100
inked to NHS-Sepharose. Similar experiments using E45, E91, E99,
104 and E108 were unable to extract any detectable antibodies
data not shown). This highlights one of the important aspects
ssociated with the use of peptide mimetics, namely that the con-
ormation that the peptide assumes may be altered depending
n the environment in which the peptide is placed. Peptide E100
as the only peptide examined that was capable of being used
o extract anti-EG95 speciﬁc antibodies. These antibodies raised
gainst EG95 were also shown to be lethal to E. granulosus onco-
pheres in vitro. Inhibition studies using these antibodies showed
hat they were capable of being inhibited from binding to EG95-
BP by the presence of free synthetic peptide E100. The antibodies
hat were afﬁnity puriﬁed were capable of binding speciﬁcally to
G95 both in the native and recombinant forms. Since the afﬁn-
ty puriﬁed antibodies are lethal to oncospheres in vitro, E100 does
imic a protective epitope of EG95. Peptides E108 and E14 both
nteract with the same antibodies as E100. E14 is capable of inhibit-
ng afﬁnity puriﬁed anti-E100 antibodies from binding to EG95
data not shown). Further information about this particular epitope
ay be deduced by comparing the amino acid sequences of these
hree peptides. The sequence KXNNDPXAA is a likely consensus
equence for this particular epitope. It would be of further interest
o produce a series of synthetic peptides containing thismotif along
ith alanine/glycine substitutions of the common residues in order
o conﬁrm which residues are essential for this peptide to act as an
pitope mimic.
Further research will need to be performed if a peptide vac-
ine is to be discovered that can protect sheep from infection
ith E. granulosus. The potential for development of a peptide-
ased vaccine is encouraged by the success that has been achieved
ith the development of a phage-based vaccine against cysticerco-
is [20]. The data presented in this paper points toward at least
ix antibody speciﬁcities being present in antibody puriﬁed to
onformation-dependant epitopes of EG95, presumably relating to
ix conformation-dependant epitopes on EG95. One of the selected
eptides is capable of afﬁnity purifying antibodies that are lethal
o E. granulosus in vitro. This peptide has the potential to be used as
he basis for determining whether protective antibodies have been
roduced in sheep vaccinated with EG95.
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